<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tourette syndrome: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tourette syndrome: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tourette syndrome: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Jankovic, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas R Nordli, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2244906007"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tourette syndrome (TS) is a neurologic disorder manifested by motor and phonic tics with onset during childhood. This topic will review the management of TS. Other aspects of TS are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6221.html" rel="external">"Tourette syndrome: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>Other hyperkinetic movement disorders are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children"</a>.)</p><p class="headingAnchor" id="H2458821219"><span class="h1">APPROACH TO MANAGEMENT</span><span class="headingEndMark"> — </span>The management of TS requires a careful assessment of the degree of functional impairment and effect on quality of life caused by tics and comorbid conditions [<a href="#rid1">1</a>]. Education is indicated for all.</p><p>Specific treatment of TS is guided by the need to treat the most troublesome symptoms, including both tics and comorbid conditions such as attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), behavioral problems, and mood disorders [<a href="#rid2">2</a>]. Therefore, it is important to determine which of these conditions is causing the greatest impairment [<a href="#rid3">3</a>]. Many patients require a combination of therapy to treat tics, ADHD, and OCD [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2000455925"><span class="h1">EDUCATION</span><span class="headingEndMark"> — </span>Education about TS, its comorbid conditions, and its natural history is important for the patient, family, peers, teachers, employers, and all who interact with the patient [<a href="#rid3">3,5,6</a>]. There is no substitute for candid discussion with the patient and family about the fluctuating nature of tics and the need to individualize therapy and tailor it to the specific needs of the patient.</p><p>Information and resources are available online from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.tsa-usa.org%2F&amp;token=3BJZCvYmVRfRODyrz5bX%2FFwUsowRvQeh2nfm7sEpVmw%3D&amp;TOPIC_ID=126069" target="_blank">Tourette Association of America</a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ftourette.ca%2F&amp;token=7d%2BIfqTVvx4PcaWIi7SF9qENe2VW8ZGxQUTX2ffddoY%3D&amp;TOPIC_ID=126069" target="_blank">Tourette Canada</a>, and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ftsaoai.wildapricot.org%2F&amp;token=TK3AyXFzwbiUTSrab38ut3WmuaGPA9EmtDxf6diCrjdX2VTaOSS1lMeaq2%2BxNoJ9&amp;TOPIC_ID=126069" target="_blank">Tourette Syndrome Association of Australia</a>.</p><p class="headingAnchor" id="H697737342"><span class="h1">MANAGEMENT OF TICS</span><span class="headingEndMark"> — </span>Intervention is indicated when symptoms of TS are interfering with social interactions, school or job performance, activities of daily living, or causing subjective discomfort, pain, or injury [<a href="#rid2">2,3,5,7</a>].</p><p>The main goal of treatment is to reduce the frequency of tics in order to improve function and quality of life [<a href="#rid3">3,5</a>]. However, there is no cure for TS, and treatment for tics seldom leads to complete cessation of tics [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2789309233"><span class="h2">Mild tics</span><span class="headingEndMark"> — </span>Patients with TS who have tics that are mild and nondisabling should receive education, counseling, and supportive care; behavioral or pharmacologic tic suppression therapy is not clearly indicated [<a href="#rid4">4</a>]. This approach has been termed "watchful waiting" and is acceptable for those without functional impairment from their tics [<a href="#rid5">5</a>]. Patients are typically followed clinically with monitoring visits every 6 to 12 months  (<a class="graphic graphic_algorithm graphicRef143357" href="/z/d/graphic/143357.html" rel="external">algorithm 1</a>). (See <a class="local">'Education'</a> above.)</p><p class="headingAnchor" id="H2823695411"><span class="h2">Debilitating tics</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with TS and tics that are causing psychosocial, physical, functional, or other problems, we suggest habit reversal training with Comprehensive Behavioral Intervention for Tics (CBIT) where access to this therapy is available, rather than treatment with medication  (<a class="graphic graphic_algorithm graphicRef143357" href="/z/d/graphic/143357.html" rel="external">algorithm 1</a>). (See <a class="local">'Habit reversal training'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When CBIT is not an option, we suggest pharmacologic treatment; options include <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> or <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a> (for children with comorbid attention deficit hyperactivity disorder [ADHD]), <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">tetrabenazine</a>, <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a>, <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">topiramate</a>, <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">fluphenazine</a>, and tiapride (not available in the United States). (See <a class="local">'Alpha adrenergic agonists'</a> below and <a class="local">'Antidopaminergic drugs'</a> below and <a class="local">'Topiramate'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with TS who have only focal motor or phonic tics, and patients who have repetitive, violent neck extension tics, we suggest treatment with botulinum toxin injections into the affected muscles. (See <a class="local">'Botulinum toxin injection'</a> below.)</p><p></p><p class="headingAnchor" id="H3743727971"><span class="h3">Habit reversal training</span><span class="headingEndMark"> — </span>A behavioral therapy called habit reversal training (HRT) may be effective for improving tics and controlling symptoms in TS [<a href="#rid8">8-10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components</strong> – HRT consists of two main components. These are [<a href="#rid11">11</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tic-awareness training, which teaches patients to recognize early signs that precede the onset of a tic</p><p class="bulletIndent2"><span class="glyph">•</span>Competing-response training, which teaches patients to perform a voluntary movement that is incompatible with the particular type of tic</p><p></p><p class="bulletIndent1">CBIT is based primarily on HRT and adds a third component of relaxation training and functional intervention to identify and mitigate situations that may exacerbate tic severity [<a href="#rid9">9</a>]. Where access is available, we suggest HRT with CBIT as initial therapy for patients with TS and debilitating tics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – A systematic review and meta-analysis of eight trials involving 438 subjects with TS who were treated with behavioral therapy (either HRT or CBIT) concluded that behavioral therapy produced moderate treatment effects and that participants receiving behavioral therapy were more likely to exhibit a treatment response compared with control interventions [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">One of the largest trials in the meta-analysis randomly assigned 126 children (ages 9 to 17 years) with TS to either behavioral therapy, consisting mainly of HRT, or to control treatment, consisting of supportive therapy and education [<a href="#rid9">9,12</a>]. Outcome evaluators were blind to treatment allocation. After 10 weeks of treatment, the group assigned to behavioral therapy had a significantly greater reduction on the total tic score of the Yale Global Tic Severity Scale compared with the control group (-7.6 versus -3.5, group difference 4.1, 95% CI 2.0-6.2). The group difference of 4.1 was considered clinically meaningful. In addition, the behavioral therapy group had a significantly greater improvement on a global measure of overall treatment response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limitations</strong> – Because of some barriers, only a limited number of patients are able to access CBIT as compared with pharmacologic treatment, which actually may be more effective. CBIT is generally not covered by insurance and there is an insufficient number of well-trained therapists. Furthermore, the success of this behavioral management is critically dependent on active involvement of the parents and the therapist, both of whom must be skilled in the various HRT and CBIT techniques. Given the demands on time and effort on the part of the patient, the therapist, and parents, it is unlikely that all parties will be able to maintain the needed compliance with the training program to provide sustained benefit. There is also some concern as to whether the mental effort required to fully comply with the various components of CBIT could actually interfere with patient's attention and learning.</p><p></p><p class="bulletIndent1">While there has been a great deal of effort exerted over the last several decades making the scientific, clinical, and lay community understand the biologic basis of TS, the reported response to behavioral therapy may be misinterpreted by some as evidence that tics and TS are of psychologic etiology. This is one reason, albeit wrong, why behavioral therapies are often not covered by insurance or other third-party payers.</p><p></p><p class="bulletIndent1">To overcome some of the limitations of access, alternative modes of delivery are being explored for various forms of psychotherapy [<a href="#rid13">13,14</a>]. One example in TS is internet-delivered, therapist-supported exposure and response prevention (ERP), which in a randomized trial in 224 patients with TS was more effective for tic reduction than a psychoeducation control [<a href="#rid13">13</a>].</p><p></p><p class="headingAnchor" id="H3834542756"><span class="h3">Alpha adrenergic agonists</span><span class="headingEndMark"> — </span>The alpha adrenergic agonists <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> and <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a> are effective for treating the symptoms of ADHD and may be helpful in patients with TS who have ADHD or predominant behavioral symptoms, particularly impulse control problems and rage attacks. (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Alpha-2-adrenergic agonists'</a>.)</p><p>Data from randomized trials suggest that <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a> [<a href="#rid15">15-19</a>] and <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> [<a href="#rid20">20-22</a>] are useful for suppressing tics [<a href="#rid23">23</a>], but the evidence for tic reduction with these agents is not consistent. In some trials, alpha adrenergic agonists were no better than placebo for reducing tics [<a href="#rid16">16,21,22</a>], and indirect evidence suggests that the magnitude of effect is less than that of the dopamine antagonists [<a href="#rid4">4,24</a>]. Nevertheless, meta-analyses have concluded that there is moderate confidence that clonidine is more effective for tic reduction compared with placebo, whereas there is low confidence that guanfacine is more effective than placebo [<a href="#rid10">10,24</a>].</p><p>Although alpha adrenergic agonists are only modestly effective against tics, they are used by some, particularly pediatricians and pediatric psychiatrists, as first-line therapy in patients with early or mild tics. When choosing an alpha adrenergic agonist, <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> may be preferred over <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a> because it is less sedating and can be given in fewer daily doses [<a href="#rid25">25</a>].</p><p>Suggested dosing regimens of <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> and <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a> for children with ADHD, and potential adverse effects, are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents"</a>.)</p><p class="headingAnchor" id="H795568570"><span class="h3">Antidopaminergic drugs</span><span class="headingEndMark"> — </span>In the United States, the only approved drugs for the treatment of TS are <a class="drug drug_pediatric" data-topicid="13347" href="/z/d/drug information/13347.html" rel="external">haloperidol</a>, <a class="drug drug_pediatric" data-topicid="13017" href="/z/d/drug information/13017.html" rel="external">pimozide</a>, and <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">aripiprazole</a>. All of these drugs act by blocking dopamine receptors and, as such, may cause tardive dyskinesia. While in the past we have used drugs that block dopamine receptors, such as <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">fluphenazine</a> or <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">risperidone</a>, we have gradually shifted to dopamine depleters, such as <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">tetrabenazine</a>, <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a>, and <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">valbenazine</a>, as the initial drugs of choice for patients with troublesome tics [<a href="#rid26">26-29</a>]. These drugs deplete dopamine by inhibiting vesicular monoamine transporter type 2 (VMAT2), and are particularly useful because observational data suggest that they are at least as effective as the typical neuroleptics, but do not cause tardive dyskinesia [<a href="#rid1">1,27,30</a>].</p><p>Practice may vary regionally, however, based on availability of VMAT2 inhibitors and other factors. As an example, European clinical guidelines for TS do not include VMAT2 inhibitors as an evidence-based treatment option; in a survey of experts, the top three recommended agents in decreasing order of preference were, for children, <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">aripiprazole</a>, <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a>, and tiapride (a benzamide antipsychotic with selective D2/D3 receptor antagonism, not available in the United States) and, for adults, aripiprazole, <a class="drug drug_pediatric" data-topicid="13347" href="/z/d/drug information/13347.html" rel="external">haloperidol</a>, and clonidine [<a href="#rid31">31</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>VMAT2 inhibitors</strong> – The typical starting dose of <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">tetrabenazine</a> for a child with TS is 6.25 mg twice a day and the dose is gradually increased in weekly intervals up to a total of 75 mg per day in three divided doses, depending on the age of the patient, clinical response, and adverse effects. Analysis for CYP2D6 genotype to determine metabolizer status for patients prescribed doses &gt;50 mg/day is recommended by some but is usually not necessary [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">Adverse effects of <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">tetrabenazine</a> include sedation, akathisia, parkinsonism, and depressed mood. There is also a risk of suicidality.</p><p></p><p class="bulletIndent1">Other VMAT2 inhibitors currently available in the United States include <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a> and <a class="drug drug_general" data-topicid="112668" href="/z/d/drug information/112668.html" rel="external">valbenazine</a> [<a href="#rid33">33</a>]. However, the improvement observed in the open-label studies of deutetrabenazine could not be replicated in two randomized double-blind placebo-controlled trials (ARTISTS1 [<a href="#rid34">34</a>] and ARTISTS2 [<a href="#rid35">35</a>]) involving 119 and 158 patients with TS, respectively [<a href="#rid36">36</a>]. There are many possible explanations for the unexpected negative results, including difficulties in assessing a highly variable disorder and subtherapeutic dosing. Indeed, long-term, open-label extension of these short-term controlled trials clearly shows the benefit of deutetrabenazine in suppressing tics. Given the benefits observed in real-world experience and open-label trials, as well as good tolerability without significant depression or risk of tardive dyskinesia, VMAT2 inhibitors should be considered as potential therapies before the introduction of antipsychotic medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antipsychotics</strong> – Although <a class="drug drug_pediatric" data-topicid="13347" href="/z/d/drug information/13347.html" rel="external">haloperidol</a>, <a class="drug drug_pediatric" data-topicid="13017" href="/z/d/drug information/13017.html" rel="external">pimozide</a>, and <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">aripiprazole</a> are the only drugs approved by the US Food and Drug Administration (FDA) for the treatment of TS, they are not frequently used because of potentially serious adverse effects. If patients do not adequately respond to alpha adrenergic agonists, they may respond to one of the following antipsychotic agents to control their tics: <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">fluphenazine</a> (starting at 1 mg daily, and increasing in 0.5 mg to 1 mg increments every week based upon response and tolerability, with a usual dose range of 0.25 to 10 mg/day), aripiprazole (2.5 to 20 mg/day), or <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">risperidone</a> (0.5 to 5 mg per day).</p><p></p><p class="bulletIndent1">Common adverse effects of first-generation antipsychotics (eg, <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">fluphenazine</a>) include parkinsonism, akathisia, acute dystonic reactions, tardive dyskinesia, and hyperprolactinemia.</p><p></p><p class="bulletIndent1">Adverse effects associated with second-generation antipsychotics (eg, <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">aripiprazole</a>, <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">risperidone</a>) include metabolic side effect, QT interval prolongation, akathisia, and tardive dyskinesia. Risperidone also causes parkinsonism. Children, especially pre-adolescents, are more susceptible to the metabolic adverse effects (weight gain, diabetes, hyperlipidemia) than older patients. A table provides a recommended schedule for monitoring metabolic effects of first and second-generation antipsychotics  (<a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">table 1</a>).</p><p></p><p>Other antidopaminergic strategies are under investigation. As an example, ecopipam is an oral selective D1 receptor antagonist that is being studied in TS as well as other disorders. In two short-term trials in children and adolescents with TS, ecopipam reduced tic severity compared with placebo and was well tolerated [<a href="#rid37">37,38</a>]. The most common side effects were headache, insomnia, fatigue, and somnolence. Neither weight gain nor tardive dyskinesia was observed with up to 12 weeks of treatment. Longer studies in a more diverse patient population are needed.</p><p class="headingAnchor" id="H552889881"><span class="h3">Topiramate</span><span class="headingEndMark"> — </span>Evidence from small randomized controlled trials suggests that <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">topiramate</a> provides short-term benefit for tic suppression in patients with TS [<a href="#rid39">39,40</a>]. Although larger and longer-term trials are needed to confirm the efficacy and tolerability of topiramate in the treatment of TS, a trial may be preferred before committing a patient to an antipsychotic agent since its side effect profile is more favorable.</p><p class="headingAnchor" id="H3934917748"><span class="h3">Botulinum toxin injection</span><span class="headingEndMark"> — </span>Focal motor and phonic tics may be treated effectively with injections of botulinum toxin into the affected muscles [<a href="#rid41">41-44</a>]. In a single randomized controlled clinical trial of 18 patients with simple motor tics, botulinum toxin treatment resulted in a significant decline in the number of tics per minute within two weeks of injection compared with placebo (39 percent reduction versus 6 percent increase) [<a href="#rid42">42</a>]. Botulinum toxin may be effective not only for the treatment of motor tics, such as blinking and cervical dystonic tics but also for the local premonitory urge [<a href="#rid10">10</a>], although high-quality evidence is lacking [<a href="#rid45">45</a>]. Patients with repetitive, violent neck extension ("whiplash") tics can be treated with botulinum toxin injections into the affected neck muscles early to prevent secondary compressive cervical myelopathy [<a href="#rid46">46</a>]. Patients with severe, loud screaming tics (even when associated with coprolalia) have been reported to benefit from botulinum toxin injections into vocal cords.</p><p class="headingAnchor" id="H2642832577"><span class="h2">Failure of initial therapy</span><span class="headingEndMark"> — </span>When initial therapy with CBIT is unsuccessful or patients are unable to access CBIT, reasonable options include pharmacotherapy with a dopamine depleting drug, a dopamine blocking drug, an alpha adrenergic agonist, or <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">topiramate</a>. Botulinum toxin is particularly helpful in focal tics, such as blinking and cervical tics.</p><p>Patients with TS who have disabling tics that are refractory to optimal medical management, including various dopamine depleters and dopamine receptor blockers, may be candidates for deep brain stimulation (DBS) of globus pallidus, thalamus, or other subcortical targets [<a href="#rid47">47-50</a>]. Preliminary evidence, while inconsistent, suggests that DBS can lead to symptomatic improvement in tics but is associated with a high rate of adverse events [<a href="#rid51">51-56</a>]. Larger clinical trials are needed to determine whether DBS is safe and beneficial for controlling tics in patients with TS.</p><p class="headingAnchor" id="H3326455168"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>Although there is no fixed time to stop treatment, it is reasonable to gradually taper off drug therapy for tics after age 18 years, at which time tics often spontaneously resolve [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H1685246093"><span class="h1">MANAGEMENT OF COMORBIDITIES</span></p><p class="headingAnchor" id="H372510759"><span class="h2">Attention deficit hyperactivity disorder</span><span class="headingEndMark"> — </span>Attention deficit hyperactivity disorder (ADHD) is often associated with TS. Behavioral interventions are preferred as the initial intervention for ADHD in preschool children (age 4 through 5 years) and as adjuncts to ADHD medication for school-aged children and adolescents. Medication options that treat both tics and ADHD include the alpha adrenergic agonists <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> and <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a>. (See <a class="local">'Alpha adrenergic agonists'</a> above.)</p><p>When central nervous system (CNS) stimulants are required to control ADHD symptoms in the setting of tics, we prefer to treat the tics first with an alpha-adrenergic agonist (eg, <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a>, <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a>) before initiating CNS stimulants such as <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">methylphenidate</a>, <a class="drug drug_pediatric" data-topicid="13010" href="/z/d/drug information/13010.html" rel="external">dexmethylphenidate</a>, <a class="drug drug_pediatric" data-topicid="17133" href="/z/d/drug information/17133.html" rel="external">methamphetamine</a>, or <a class="drug drug_pediatric" data-topicid="13218" href="/z/d/drug information/13218.html" rel="external">dextroamphetamine</a>, because clinical experience suggests that these drugs tend to trigger or exacerbate tics. We find <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">atomoxetine</a>, a non-stimulator, only modestly effective in the treatment of TS-related ADHD. Antidopaminergic drugs may be used as second-line therapies for worsening tics. (See  <a class="medical medical_review" href="/z/d/html/623.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis"</a>.)</p><p>Other experts prefer to start treatment for ADHD and closely follow tic severity, despite concerns that CNS stimulants may precipitate or exacerbate tics [<a href="#rid57">57</a>]. A meta-analysis found that <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">methylphenidate</a> did not worsen tic severity among four placebo-controlled randomized trials involving 191 subjects with both TS and ADHD [<a href="#rid58">58</a>]. In addition, a later meta-analysis of 22 studies involving 2385 children with ADHD and no tic disorder at baseline found that psychostimulant treatment compared with placebo did not increase the risk of new-onset or worsening tics [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/621.html" rel="external">"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents", section on 'Stimulant adverse effects'</a>.)</p><p class="headingAnchor" id="H1008946013"><span class="h2">Obsessive-compulsive disorder</span><span class="headingEndMark"> — </span>For children who have TS and comorbid obsessive-compulsive disorder (OCD), the suggested initial treatment of OCD is cognitive-behavioral therapy (CBT) with or without pharmacotherapy with a selective serotonin reuptake inhibitor (SSRI). Antipsychotic therapy may be used selectively for severe tics that persist despite these therapies. Management of OCD, including tic-related OCD, is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/90748.html" rel="external">"Obsessive-compulsive disorder in children and adolescents: Treatment overview", section on 'Treatment of associated syndromes'</a>.)</p><p class="headingAnchor" id="H2039238782"><span class="h1">GENETIC COUNSELING</span><span class="headingEndMark"> — </span>While there is evidence of a genetic component in the etiology of TS [<a href="#rid60">60</a>], the pathogenesis is complex, and the genetic basis of TS remains poorly understood. (See  <a class="medical medical_review" href="/z/d/html/6221.html" rel="external">"Tourette syndrome: Pathogenesis, clinical features, and diagnosis", section on 'Pathogenesis'</a>.)</p><p>The rate of TS in parents of an affected child has been reported to be up to 16 percent [<a href="#rid61">61</a>], although the rate is much higher if a parental history of childhood tics, attention deficit hyperactivity disorder (ADHD), or obsessive-compulsive disorder (OCD) is considered. Using rigorous diagnostic criteria, one study found that both parents had some features of TS or an associated disorder (tics, OCD, or ADHD), so-called bilineal transmission, in at least 25 percent of TS cases [<a href="#rid62">62</a>].</p><p>Most but not all studies suggest that the prevalence of TS is similar among different ethnic groups [<a href="#rid61">61</a>]. However, a population study from Japan found a comparatively low rate of TS in both parents (approximately 2 percent) [<a href="#rid63">63</a>].</p><p>In siblings of an affected child, the risk of TS is approximately 8 percent in most studies [<a href="#rid61">61</a>] but was 2 percent in the Japanese population study [<a href="#rid63">63</a>]. The risk of OCD in siblings is 10 to 22 percent, while the risk for chronic tics in siblings ranges from 0 to 11 percent [<a href="#rid64">64,65</a>].</p><p>For offspring of parents with TS, a prospective longitudinal study found that the overall empiric risk of TS was 22 percent, while the risk of any tic disorder was &gt;50 percent [<a href="#rid66">66</a>]. The risk of TS was increased in bilineal families (43 percent, compared with 15 percent for unilineal families). Additionally, the rates of any tic diagnosis, OCD, and ADHD were increased in bilineal compared with unilineal families [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H1138924176"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Tics often decline during adolescence and young adulthood and even resolve in a substantial minority. The natural history of TS is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6221.html" rel="external">"Tourette syndrome: Pathogenesis, clinical features, and diagnosis", section on 'Onset and natural history'</a>.)</p><p class="headingAnchor" id="H4123554970"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121121.html" rel="external">"Society guideline links: Tourette syndrome"</a>.)</p><p class="headingAnchor" id="H2174211761"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/83754.html" rel="external">"Patient education: Tourette syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3995893293"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> – Specific treatment of Tourette syndrome (TS) is guided by the need to treat the most troublesome symptoms, including both tics and comorbid conditions such as attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). Education is indicated for all. (See <a class="local">'Approach to management'</a> above and <a class="local">'Education'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild, nondisabling tics</strong> – Patients with TS who have tics that are mild and nondisabling should receive education, counseling, and supportive care; behavioral or pharmacologic tic suppression therapy is not clearly indicated  (<a class="graphic graphic_algorithm graphicRef143357" href="/z/d/graphic/143357.html" rel="external">algorithm 1</a>). (See <a class="local">'Mild tics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with comorbid ADHD</strong> – For patients who have TS and ADHD, behavioral interventions are preferred to medication as the initial treatment for ADHD in preschool children and as adjuncts to medication for school-aged children and adolescents. Medication options that treat both tics and ADHD include the alpha adrenergic agonists <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> or <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a>. (See <a class="local">'Attention deficit hyperactivity disorder'</a> above and <a class="local">'Alpha adrenergic agonists'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with comorbid OCD</strong> – For children who have TS and comorbid OCD, cognitive-behavioral therapy with or without pharmacotherapy with a selective serotonin reuptake inhibitor (SSRI) is the preferred initial treatment. (See  <a class="medical medical_review" href="/z/d/html/90748.html" rel="external">"Obsessive-compulsive disorder in children and adolescents: Treatment overview", section on 'Treatment of associated syndromes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Debilitating tics </strong> (<a class="graphic graphic_algorithm graphicRef143357" href="/z/d/graphic/143357.html" rel="external">algorithm 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with TS and tics that are causing psychosocial, physical, functional, or other problems, we suggest habit reversal training with Comprehensive Behavioral Intervention for Tics (CBIT) where access to this therapy is available, rather than treatment with medication (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Habit reversal training'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When CBIT is not an option for patients with TS and debilitating tics, we suggest medication treatment with <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">tetrabenazine</a> or <a class="drug drug_general" data-topicid="112590" href="/z/d/drug information/112590.html" rel="external">deutetrabenazine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternatives include <a class="drug drug_pediatric" data-topicid="12851" href="/z/d/drug information/12851.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">fluphenazine</a>, <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">aripiprazole</a>, and <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">risperidone</a>. (See <a class="local">'Antidopaminergic drugs'</a> above and <a class="local">'Topiramate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with TS who have only focal motor or phonic tics, we suggest treatment with botulinum toxin injections into the affected muscles (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Botulinum toxin injection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic counseling</strong> – In siblings of an affected child, the risk of TS is approximately 8 percent in most studies. For offspring of a parent with TS, the empiric risk of TS is approximately 15 percent. (See <a class="local">'Genetic counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Tics often decline during adolescence and young adulthood and even resolve in a substantial minority. The natural history of TS is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6221.html" rel="external">"Tourette syndrome: Pathogenesis, clinical features, and diagnosis", section on 'Onset and natural history'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jankovic J. Treatment of tics associated with Tourette syndrome. J Neural Transm (Vienna) 2020; 127:843.</a></li><li><a class="nounderline abstract_t">Cothros N, Medina A, Pringsheim T. Current pharmacotherapy for tic disorders. Expert Opin Pharmacother 2020; 21:567.</a></li><li><a class="nounderline abstract_t">Singer HS. Tics and Tourette Syndrome. Continuum (Minneap Minn) 2019; 25:936.</a></li><li><a class="nounderline abstract_t">Billnitzer A, Jankovic J. Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics 2020; 17:1681.</a></li><li><a class="nounderline abstract_t">Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 2019; 92:896.</a></li><li><a class="nounderline abstract_t">Nussey C, Pistrang N, Murphy T. How does psychoeducation help? A review of the effects of providing information about Tourette syndrome and attention-deficit/hyperactivity disorder. Child Care Health Dev 2013; 39:617.</a></li><li><a class="nounderline abstract_t">Jaffe RJ, Coffey BJ. Pharmacologic Treatment of Comorbid Attention-Deficit/Hyperactivity Disorder and Tourette and Tic Disorders. Child Adolesc Psychiatr Clin N Am 2022; 31:469.</a></li><li><a class="nounderline abstract_t">McGuire JF, Piacentini J, Brennan EA, et al. A meta-analysis of behavior therapy for Tourette Syndrome. J Psychiatr Res 2014; 50:106.</a></li><li><a class="nounderline abstract_t">Piacentini J, Woods DW, Scahill L, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA 2010; 303:1929.</a></li><li><a class="nounderline abstract_t">Pringsheim T, Holler-Managan Y, Okun MS, et al. Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 2019; 92:907.</a></li><li><a class="nounderline abstract_t">Azrin NH, Nunn RG. Habit-reversal: a method of eliminating nervous habits and tics. Behav Res Ther 1973; 11:619.</a></li><li><a class="nounderline abstract_t">Espil FM, Woods DW, Specht MW, et al. Long-term Outcomes of Behavior Therapy for Youth With Tourette Disorder. J Am Acad Child Adolesc Psychiatry 2022; 61:764.</a></li><li><a class="nounderline abstract_t">Hollis C, Hall CL, Jones R, et al. Therapist-supported online remote behavioural intervention for tics in children and adolescents in England (ORBIT): a multicentre, parallel group, single-blind, randomised controlled trial. Lancet Psychiatry 2021; 8:871.</a></li><li><a class="nounderline abstract_t">Andrén P, Holmsved M, Ringberg H, et al. Therapist-Supported Internet-Delivered Exposure and Response Prevention for Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open 2022; 5:e2225614.</a></li><li><a class="nounderline abstract_t">Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58:527.</a></li><li><a class="nounderline abstract_t">Goetz CG, Tanner CM, Wilson RS, et al. Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods. Ann Neurol 1987; 21:307.</a></li><li><a class="nounderline abstract_t">Gaffney GR, Perry PJ, Lund BC, et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 2002; 41:330.</a></li><li><a class="nounderline abstract_t">Du YS, Li HF, Vance A, et al. Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 2008; 42:807.</a></li><li><a class="nounderline abstract_t">Leckman JF, Hardin MT, Riddle MA, et al. Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1991; 48:324.</a></li><li><a class="nounderline abstract_t">Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158:1067.</a></li><li><a class="nounderline abstract_t">Cummings DD, Singer HS, Krieger M, et al. Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. Clin Neuropharmacol 2002; 25:325.</a></li><li><a class="nounderline abstract_t">Murphy TK, Fernandez TV, Coffey BJ, et al. Extended-Release Guanfacine Does Not Show a Large Effect on Tic Severity in Children with Chronic Tic Disorders. J Child Adolesc Psychopharmacol 2017; 27:762.</a></li><li><a class="nounderline abstract_t">Weisman H, Qureshi IA, Leckman JF, et al. Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev 2013; 37:1162.</a></li><li><a class="nounderline abstract_t">Farhat LC, Behling E, Landeros-Weisenberger A, et al. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. Lancet Child Adolesc Health 2023; 7:112.</a></li><li><a class="nounderline abstract_t">Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord 2011; 26:1149.</a></li><li><a class="nounderline abstract_t">Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2009; :CD006996.</a></li><li><a class="nounderline abstract_t">Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006; 6:7.</a></li><li><a class="nounderline abstract_t">Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 2014; 29:126.</a></li><li><a class="nounderline abstract_t">Jankovic J. Therapeutic Developments for Tics and Myoclonus. Mov Disord 2015; 30:1566.</a></li><li><a class="nounderline abstract_t">Niemann N, Jankovic J. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol 2019; 42:37.</a></li><li><a class="nounderline abstract_t">Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry 2022; 31:425.</a></li><li><a class="nounderline abstract_t">Mehanna R, Hunter C, Davidson A, et al. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord 2013; 28:210.</a></li><li><a class="nounderline abstract_t">Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 2016; 17:2461.</a></li><li><a class="nounderline abstract_t">Jankovic J, Coffey B, Claassen DO, et al. Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open 2021; 4:e2128204.</a></li><li><a class="nounderline abstract_t">Coffey B, Jankovic J, Claassen DO, et al. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open 2021; 4:e2129397.</a></li><li><a class="nounderline abstract_t">Baron MS. Lack of Support for the Use of VMAT-2 Inhibitors for the Treatment of Tics in Tourette Syndrome. JAMA Netw Open 2021; 4:e2129704.</a></li><li><a class="nounderline abstract_t">Gilbert DL, Dubow JS, Cunniff TM, et al. Ecopipam for Tourette Syndrome: A Randomized Trial. Pediatrics 2023; 151.</a></li><li><a class="nounderline abstract_t">Gilbert DL, Murphy TK, Jankovic J, et al. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord 2018; 33:1272.</a></li><li><a class="nounderline abstract_t">Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010; 81:70.</a></li><li><a class="nounderline abstract_t">Yang CS, Zhang LL, Zeng LN, et al. Topiramate for Tourette's syndrome in children: a meta-analysis. Pediatr Neurol 2013; 49:344.</a></li><li><a class="nounderline abstract_t">Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord 1996; 11:431.</a></li><li><a class="nounderline abstract_t">Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001; 56:605.</a></li><li><a class="nounderline abstract_t">Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 2000; 57:1190.</a></li><li><a class="nounderline abstract_t">Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci 2004; 24:420.</a></li><li><a class="nounderline abstract_t">Pandey S, Srivanitchapoom P, Kirubakaran R, Berman BD. Botulinum toxin for motor and phonic tics in Tourette's syndrome. Cochrane Database Syst Rev 2018; 1:CD012285.</a></li><li><a class="nounderline abstract_t">Lotia M, Jankovic J. Botulinum Toxin for the Treatment of Tremor and Tics. Semin Neurol 2016; 36:54.</a></li><li><a class="nounderline abstract_t">Schrock LE, Mink JW, Woods DW, et al. Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord 2015; 30:448.</a></li><li><a class="nounderline abstract_t">Deeb W, Malaty I. Deep Brain Stimulation for Tourette Syndrome: Potential Role in the Pediatric Population. J Child Neurol 2020; 35:155.</a></li><li><a class="nounderline abstract_t">Jimenez-Shahed J. Medical and Surgical Treatments of Tourette Syndrome. Neurol Clin 2020; 38:349.</a></li><li><a class="nounderline abstract_t">Martino D, Deeb W, Jimenez-Shahed J, et al. The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection: Present and Future. Neurology 2021; 96:664.</a></li><li><a class="nounderline abstract_t">Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg 2012; 90:213.</a></li><li><a class="nounderline abstract_t">Zhang JG, Ge Y, Stead M, et al. Long-term outcome of globus pallidus internus deep brain stimulation in patients with Tourette syndrome. Mayo Clin Proc 2014; 89:1506.</a></li><li><a class="nounderline abstract_t">Kefalopoulou Z, Zrinzo L, Jahanshahi M, et al. Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. Lancet Neurol 2015; 14:595.</a></li><li><a class="nounderline abstract_t">Welter ML, Houeto JL, Thobois S, et al. Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial. Lancet Neurol 2017; 16:610.</a></li><li><a class="nounderline abstract_t">Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, et al. Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. JAMA Neurol 2018; 75:353.</a></li><li><a class="nounderline abstract_t">Johnson KA, Fletcher PT, Servello D, et al. Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite study. J Neurol Neurosurg Psychiatry 2019; 90:1078.</a></li><li><a class="nounderline abstract_t">Piacentini J, Chang S. Behavioral treatments for Tourette syndrome and tic disorders: state of the art. Adv Neurol 2001; 85:319.</a></li><li><a class="nounderline abstract_t">Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009; 48:884.</a></li><li><a class="nounderline abstract_t">Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. J Am Acad Child Adolesc Psychiatry 2015; 54:728.</a></li><li><a class="nounderline abstract_t">Mataix-Cols D, Isomura K, Pérez-Vigil A, et al. Familial Risks of Tourette Syndrome and Chronic Tic Disorders. A Population-Based Cohort Study. JAMA Psychiatry 2015; 72:787.</a></li><li class="breakAll">Stillman A, Ercan-Sencicek AG, State MW. Tourette disorder overview. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK21138/ (Accessed on June 10, 2011).</li><li><a class="nounderline abstract_t">Hanna PA, Janjua FN, Contant CF, Jankovic J. Bilineal transmission in Tourette syndrome. Neurology 1999; 53:813.</a></li><li><a class="nounderline abstract_t">Kano Y, Ohta M, Nagai Y, et al. A family study of Tourette syndrome in Japan. Am J Med Genet 2001; 105:414.</a></li><li><a class="nounderline abstract_t">Pauls DL, Raymond CL, Stevenson JM, Leckman JF. A family study of Gilles de la Tourette syndrome. Am J Hum Genet 1991; 48:154.</a></li><li><a class="nounderline abstract_t">Walkup JT, LaBuda MC, Singer HS, et al. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 1996; 59:684.</a></li><li><a class="nounderline abstract_t">McMahon WM, Carter AS, Fredine N, Pauls DL. Children at familial risk for Tourette's disorder: Child and parent diagnoses. Am J Med Genet B Neuropsychiatr Genet 2003; 121B:105.</a></li></ol></div><div id="topicVersionRevision">Topic 126069 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31955299" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of tics associated with Tourette syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32286097" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Current pharmacotherapy for tic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356288" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tics and Tourette Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32856174" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31061208" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23461278" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : How does psychoeducation help? A review of the effects of providing information about Tourette syndrome and attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35697396" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pharmacologic Treatment of Comorbid Attention-Deficit/Hyperactivity Disorder and Tourette and Tic Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398255" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A meta-analysis of behavior therapy for Tourette Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20483969" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Behavior therapy for children with Tourette disorder: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31061209" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4777653" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Habit-reversal: a method of eliminating nervous habits and tics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34508805" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-term Outcomes of Behavior Therapy for Youth With Tourette Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34480868" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Therapist-supported online remote behavioural intervention for tics in children and adolescents in England (ORBIT): a multicentre, parallel group, single-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35969401" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Therapist-Supported Internet-Delivered Exposure and Response Prevention for Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865128" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of ADHD in children with tics: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3300518" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11886028" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18696285" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Randomized double-blind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2009034" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clonidine treatment of Gilles de la Tourette's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431228" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12469007" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28723227" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Extended-Release Guanfacine Does Not Show a Large Effect on Tic Severity in Children with Chronic Tic Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23099282" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36528030" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21484868" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tourette syndrome: evolving concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370666" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pimozide for tics in Tourette's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16466307" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tetrabenazine in the treatment of hyperkinetic movement disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24150997" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26315614" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Therapeutic Developments for Tics and Myoclonus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30870235" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Real-World Experience With VMAT2 Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34757514" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23280482" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Analysis of CYP2D6 genotype and response to tetrabenazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27819145" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dopamine depleters in the treatment of hyperkinetic movement disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34609495" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34661664" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34661669" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lack of Support for the Use of VMAT-2 Inhibitors for the Treatment of Tics in Tourette Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36628546" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ecopipam for Tourette Syndrome: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30192018" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19726418" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24139534" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Topiramate for Tourette's syndrome in children: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8813224" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11245710" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10927800" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Botulinum toxin in the treatment of tics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767691" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29304272" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Botulinum toxin for motor and phonic tics in Tourette's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26866497" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Botulinum Toxin for the Treatment of Tremor and Tics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25476818" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Tourette syndrome deep brain stimulation: a review and updated recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31526168" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Deep Brain Stimulation for Tourette Syndrome: Potential Role in the Pediatric Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32279714" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Medical and Surgical Treatments of Tourette Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33593864" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection: Present and Future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22699684" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Deep brain stimulation for Tourette syndrome: target selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25444487" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term outcome of globus pallidus internus deep brain stimulation in patients with Tourette syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25882029" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28645853" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29340590" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31129620" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11530440" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Behavioral treatments for Tourette syndrome and tic disorders: state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19625978" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26299294" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26083307" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Familial Risks of Tourette Syndrome and Chronic Tic Disorders. A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26083307" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Familial Risks of Tourette Syndrome and Chronic Tic Disorders. A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10489047" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bilineal transmission in Tourette syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11449392" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A family study of Tourette syndrome in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985456" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A family study of Gilles de la Tourette syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8751870" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12898584" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Children at familial risk for Tourette's disorder: Child and parent diagnoses.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
